Account Executive
BillionToOneSalary not specified
- Full Time
- Mid-level (3 to 4 years)
About BillionToOne
BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy, efficiency, and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to positively impact healthcare by making molecular testing more reliable and available to everyone.
Menlo Park, CaliforniaHeadquarters
2016Year Founded
$380.2MTotal Funding
SERIES_DCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Benefits
Competitive pay
Retirement savings package
Parental leave
Free snacks & lunches
Medical, dental, & vision premiums
On campus perks
Free-on-site EV charging
Risks
Emerging biotech startups could threaten BillionToOne's market share.
Rapid technological advancements may render their current technology obsolete.
Expansion into new facilities may face operational challenges or delays.
Differentiation
BillionToOne's QCT technology detects DNA variations at single base-pair resolution.
Their UNITY Fetal Antigen NIPT is the first US cfDNA test for fetal antigen genotyping.
They replace invasive amniocentesis with a safe, affordable blood test for prenatal screening.
Upsides
BillionToOne achieved a billion-dollar valuation with a $130 million funding round.
Their new Austin facility will create 1,000 jobs, boosting production and local economy.
Recognition as Diagnostics Company of the Year highlights their industry leadership.
Funding
Total raised$380.24 M
Latest valuation$1.00 B
StageSERIES_D
DEBT
11/30/2022$35
SERIES B
5/31/2021$55
$275.00 MSEED
8/31/2017$2
$12.00 M